| 炎症性肠病的药物治疗现状及进展 |
| |
| 引用本文： | 王英德. 炎症性肠病的药物治疗现状及进展[J]. 医学与哲学(人文社会医学版), 2014, 0(2): 7-10,26 |
| |
| 作者姓名： | 王英德 |
| |
| 作者单位： | 大连医科大学附属第一医院消化内科,辽宁大连116011 |
| |
| 基金项目： | 辽宁省科技厅科技计划项目“5-ASA纳米药物载体系统的制备及对溃疡性结肠炎大鼠靶向治疗作用的研究”,项目编号：2012225018 |
| |
| 摘 要： | 炎症性肠病（IBD）病程迁延反复，影响患者生活质量，耗费卫生资源。虽然传统药物如5-氨基水杨酸、糖皮质激素、免疫抑制剂等仍是目前治疗主流，但是大量有关发病机制的研究以及循证医学的发展对IBD的治疗产生了积极的推进作用。IBD的治疗正步入免疫调节的生物学时代，多种新型生物制剂的出现为IBD的治疗提供了新的策略和选择。现就目前IBD药物治疗现状以及最新进展进行综述，以期对临床IBD治疗提供参考。
|
| 关 键 词： | 溃疡性结肠炎 克罗恩病 生物制剂 |
Current Status and Progress of Drug Treatment in Inflammatory Bowel Disease |
| |
| WANG Ying-de. Current Status and Progress of Drug Treatment in Inflammatory Bowel Disease[J]. Medicine & Philosophy:Humanistic & Social Medicine Edition, 2014, 0(2): 7-10,26 |
| |
| Authors: | WANG Ying-de |
| |
| Affiliation: | WANG Ying-de. Department of Gastroenterology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China |
| |
| Abstract: | Patients with inflammatory bowel disease （IBD） are characterized by their persistence and reccurrence ol the disease, which affect the patients＂ quality of life and consume health resources. Although traditional drugs such as 5-ASA, glucocorticoid and immunosuppressive agents are currently still the major treatment, a large number of studies on the pathogenesis and the development of evidence-based medicine have played a positive and active role in the treatment of IBD. Treatment of IBD is moving towards the biological era of immune regulation. The emergence of a variety of new type of biological agents for the treatment of IBD has provided a new strategy and choice. In this paper, the current drug treatment status and the latest progress regarding IBD were reviewed in order to provide references for clinical treatment of IBD. |
| |
| Keywords: | ulcerative colitis Crohn＇s disease biological agent |
| 本文献已被 维普 等数据库收录！ |
